Oncology Medical News about Docetaxel, irinotecan, head and neck cancer

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Docetaxel and irinotecan in recurrent or metastatic head and neck cancer
Cancer, 07/31/09

Argiris A et al. - In a trial to evaluate combination docetaxel and irinotecan in the treatment of pts with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN), it was suggested that docetaxel and irinotecan had acceptable toxicities, but efficacy results in unselected pts with recurrent or metastatic SCCHN did not suggest an advantage over docetaxel alone or platinum-based regimens.

Methods

Eligibility criteria included recurrent or metastatic SCCHN with measurable disease, good performance status, and adequate laboratory parameters.
Pts received docetaxel 35 mg/m2 and irinotecan 60 mg/m2, intravenously, on days 1 and 8, every 21 days, until disease progression.
UGT1A1 genotype, vascular endothelial growth factor (VEGF) in serum, and cyclooxygenase-2 and VEGF were assessed in baseline tumor tissue.

Results

52 pts were analyzable: 20 chemotherapy naive (Group A) and 32 previously treated with 1 chemotherapy regimen (Group B); 73% of pts had distant metastasis, and 60% were paclitaxel-exposed.
In Group A, 3 (15%) pts achieved a partial response; in Group B, 1 (3%) pt achieved a partial response.
Median progression-free survival (PFS) and overall survival were 3.3 and 8.2 mos in Group A and 1.9 and 5.0 mos in Group B, respectively.
Common serious toxicities were diarrhea, fatigue, and anorexia.
Pts with high serum VEGF had a median PFS of 2.8 mos vs 1.7 mos for pts with low VEGF.

<< Previous
High WT1 gene expression before haematopoietic stem cell...

Next >>
Accuracy of high-resolution magnetic resonance imaging in...